Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 01/16/2026 | CALL | $230.00 | 2,187 | +1,789 | +449.50% |
| 01/16/2026 | CALL | $195.00 | 5,357 | +1,121 | +26.46% |
| 01/16/2026 | CALL | $240.00 | 1,600 | +1,000 | +166.67% |
| 01/16/2026 | CALL | $210.00 | 4,113 | +538 | +15.05% |
| 01/16/2026 | CALL | $220.00 | 2,129 | +512 | +31.66% |
| 04/17/2026 | CALL | $185.00 | 7,063 | +235 | +3.44% |
| 12/19/2025 | PUT | $190.00 | 0 | -4,625 | -100.00% |
| 12/19/2025 | PUT | $195.00 | 0 | -4,872 | -100.00% |
| 12/19/2025 | CALL | $200.00 | 0 | -5,015 | -100.00% |
| 12/19/2025 | CALL | $210.00 | 0 | -5,015 | -100.00% |
| 12/19/2025 | PUT | $200.00 | 0 | -5,015 | -100.00% |
| 12/19/2025 | CALL | $195.00 | 0 | -6,372 | -100.00% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.55% | 79.47M | 12.56B |
| Vanguard 500 Index Fund | 1.94% | 60.44M | 9.55B |
| Fidelity 500 Index Fund | 0.92% | 28.66M | 4.53B |
| SPDR S&P 500 ETF Trust | 0.91% | 28.31M | 4.47B |
| iShares Core S&P 500 ETF | 0.75% | 23.33M | 3.69B |
| Vanguard Index-Value Index Fund | 0.72% | 22.6M | 3.57B |
| Select Sector SPDR Fund-Health Care | 0.68% | 21.24M | 3.36B |
| Vanguard Institutional Index Fund-Institutional Index Fund | 0.59% | 18.32M | 2.9B |
| Vanguard Specialized-Dividend Appreciation Index Fund | 0.53% | 16.62M | 2.63B |
| Washington Mutual Investors Fund | 0.40% | 12.37M | 1.96B |
Hospital Care Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 726 Deals by Company A-Z, Therapy Focus and Technology Type
11/19 11:59 am
GlobeNewswire Inc.
Read more5 Dividend Aristocrats I Recommend Now
11/19 03:01 am
Investing.com
Read moreNailing Systems Market Set for Strong Growth as Demand Rises Across Orthopedic and Trauma Care Segments: Verified Market Research®
11/18 11:45 pm
GlobeNewswire Inc.
Read moreAI in Medical Devices Market Expands to USD 886.39 Billion by 2034 – reports Towards Healthcare
11/18 12:00 pm
GlobeNewswire Inc.
Read moreJohnson & Johnson Adds Prostate Cancer Candidate In Around $3 Billion Halda Deal
11/17 01:23 pm
Benzinga
Read moreHalda Therapeutics Announces Acquisition by Johnson & Johnson
11/17 09:15 am
Benzinga
Read moreBenitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
11/14 06:00 pm
GlobeNewswire Inc.
Read moreBristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy
11/14 12:17 pm
Benzinga
Read more2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon
11/13 06:04 am
The Motley Fool
Read moreWant Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
11/12 12:01 pm
The Motley Fool
Read moreBreast Implants Market to Surpass USD 5.62 Billion by 2034, Driven by Rising Breast Cancer Cases and Aesthetic Surgery Demand
11/11 09:00 am
GlobeNewswire Inc.
Read moreGot $1,000? Here Are the Smartest Dividend Stocks to Start With.
11/10 05:15 am
The Motley Fool
Read moreLamar Advertising (LAMR) Q3 2025 Earnings Call Transcript
11/06 12:10 pm
The Motley Fool
Read moreHigh Concentration mAb Products Market Advancing Precision Biopharmaceutical Therapeutics – Towards Healthcare
11/06 12:00 pm
GlobeNewswire Inc.
Read moreAlvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu við Simponi (golimumab)
11/06 10:00 am
GlobeNewswire Inc.
Read moreAC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
11/04 08:00 am
GlobeNewswire Inc.
Read moreThese 2 Dividend Kings Are Combining in a $48.7 Billion Megadeal. Is It A Win-Win for Dividend Investors?
11/04 04:23 am
The Motley Fool
Read morePelvic Inflammatory Disease Treatment Market to Reach USD 5.09 Billion by 2034, Driven by Rising STI Cases and Growing Awareness
11/03 12:00 pm
GlobeNewswire Inc.
Read moreKimberly-Clark Stock Plunges Over 16%, Kenvue Surges 20% In Monday Pre-Market: What's Going On?
11/03 08:16 am
Benzinga
Read moreMultiple Myeloma Research Foundation Joins Forces with Patients and Caregivers for Road to Victories Fundraiser
11/03 08:00 am
GlobeNewswire Inc.
Read moreWill President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks?
11/03 07:15 am
The Motley Fool
Read morePharmaceutical Market to Reach USD 3,033.21 Billion by 2034 Driven by Rising Geriatric Population
10/29 11:00 am
GlobeNewswire Inc.
Read moreKen Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety
10/28 01:11 pm
Benzinga
Read moreJoint Reconstruction Devices Market 2025-2032: New Technologies are Transforming the Landscape, Reaching $149 Billion by 2032
10/27 09:00 am
GlobeNewswire Inc.
Read moreFDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep
10/24 10:23 am
Benzinga
Read moreInside Dow Jones: Key Earnings Ahead for Some of the Index YTD Winners
10/22 10:40 am
Investing.com
Read moreGlobal Cataract Surgery Devices Market to Grow at a CAGR of ~5% Driven by Innovation and Increasing Patient Awareness | DelveInsight
10/21 01:00 pm
GlobeNewswire Inc.
Read moreSynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
10/21 07:00 am
GlobeNewswire Inc.
Read moreActivist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb
10/20 10:57 am
Benzinga
Read more2 Top Dividend Kings Every Income Investor Should Own
10/20 05:05 am
The Motley Fool
Read moreMeet the 5%-Yielding Dividend Stock That Could Soar in 2026
10/19 01:25 pm
The Motley Fool
Read moreSubcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
10/19 10:35 am
GlobeNewswire Inc.
Read moreWhy Kenvue Stock Tumbled by 13% on Thursday
10/16 06:06 pm
The Motley Fool
Read moreJohnson & Johnson Builds Momentum as Margin Expansion Strategy Takes Hold
10/16 02:08 pm
Investing.com
Read moreJohnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy
10/16 01:37 pm
Benzinga
Read moreJohnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims
10/16 10:18 am
Benzinga
Read moreJohnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks
10/16 09:09 am
Benzinga
Read more2 Dividend Stocks I'm Very Thankful I Owned This Year
10/15 01:03 pm
The Motley Fool
Read moreThis 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy
10/15 05:20 am
The Motley Fool
Read moreJohnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
10/14 08:51 am
Benzinga
Read moreFDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy
10/13 10:30 am
Benzinga
Read moreDrug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
10/13 06:10 am
The Motley Fool
Read moreDouglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal
10/12 03:14 pm
The Motley Fool
Read moreWhy Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
10/10 07:07 pm
The Motley Fool
Read moreJohnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
10/10 01:06 pm
Benzinga
Read more